The new WHO 2016 classification of brain tumors-what neurosurgeons need to know

被引:74
作者
Banan, Rouzbeh [1 ]
Hartmann, Christian [1 ]
机构
[1] Hannover Med Sch MHH, Inst Pathol, Dept Neuropathol, Carl Neuberg Str 1, D-30625 Hannover, Germany
关键词
Brain tumors; WHO; Classification; Neuropathology; Molecular pathology; ATYPICAL TERATOID/RHABDOID TUMORS; TERT PROMOTER MUTATIONS; MOLECULAR CLASSIFICATION; PROGNOSTIC VALUE; GRADE II; ANAPLASTIC ASTROCYTOMAS; ABUNDANT NEUROPIL; GENOMIC ANALYSIS; K27M MUTATIONS; TRUE ROSETTES;
D O I
10.1007/s00701-016-3062-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The understanding of molecular alterations of tumors has severely changed the concept of classification in all fields of pathology. The availability of high-throughput technologies such as next-generation sequencing allows for a much more precise definition of tumor entities. Also in the field of brain tumors a dramatic increase of knowledge has occurred over the last years partially calling into question the purely morphologically based concepts that were used as exclusive defining criteria in the WHO 2007 classification. Review of the WHO 2016 classification of brain tumors as well as a search and review of publications in the literature relevant for brain tumor classification from 2007 up to now. The idea of incorporating the molecular features in classifying tumors of the central nervous system led the authors of the new WHO 2016 classification to encounter inevitable conceptual problems, particularly with respect to linking morphology to molecular alterations. As a solution they introduced the concept of a "layered diagnosis" to the classification of brain tumors that still allows at a lower level a purely morphologically based diagnosis while partially forcing the incorporation of molecular characteristics for an "integrated diagnosis" at the highest diagnostic level. In this context the broad availability of molecular assays was debated. On the one hand molecular antibodies specifically targeting mutated proteins should be available in nearly all neuropathological laboratories. On the other hand, different high-throughput assays are accessible only in few first-world neuropathological institutions. As examples oligodendrogliomas are now primarily defined by molecular characteristics since the required assays are generally established, whereas molecular grouping of ependymomas, found to clearly outperform morphologically based tumor interpretation, was rejected from inclusion in the WHO 2016 classification because the required assays are currently only established in a small number of institutions. In summary, while neuropathologists have now encountered various challenges in the transitional phase from the previous WHO 2007 version to the new WHO 2016 classification of brain tumors, clinical neurooncologists now face many new diagnoses allowing a clearly improved understanding that could offer them more effective therapeutic opportunities in neurooncological treatment. The new WHO 2016 classification presumably presents the highest number of modifications since the initial WHO classification of 1979 and thereby forces all professionals in the field of neurooncology to intensively understand the new concepts. This review article aims to present the basic concepts of the new WHO 2016 brain tumor classification for neurosurgeons with a focus on neurooncology.
引用
收藏
页码:403 / 418
页数:16
相关论文
共 85 条
  • [21] Definition of Disease-Risk Stratification Groups in Childhood Medulloblastoma Using Combined Clinical, Pathologic, and Molecular Variables
    Ellison, David W.
    Kocak, Mehmet
    Dalton, James
    Megahed, Hisham
    Lusher, Meryl E.
    Ryan, Sarra L.
    Zhao, Wei
    Nicholson, Sarah Leigh
    Taylor, Roger E.
    Bailey, Simon
    Clifford, Steven C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (11) : 1400 - 1407
  • [22] Evidence of H3 K27M mutations in posterior fossa ependymomas
    Gessi, Marco
    Capper, David
    Sahm, Felix
    Huang, Kristin
    von Deimling, Andreas
    Tippelt, Stephan
    Fleischhack, Gudrun
    Scherbaum, Daniel
    Alfer, Joachim
    Juhnke, Bjoern-Ole
    von Hoff, Katja
    Rutkowski, Stefan
    Warmuth-Metz, Monika
    Chavez, Lukas
    Pfister, Stefan M.
    Pietsch, Torsten
    Jones, David T. W.
    Sturm, Dominik
    [J]. ACTA NEUROPATHOLOGICA, 2016, 132 (04) : 635 - 637
  • [23] Embryonal Tumors With Abundant Neuropil and True Rosettes A Distinctive CNS Primitive Neuroectodermal Tumor
    Gessi, Marco
    Giangaspero, Felice
    Lauriola, Libero
    Gardiman, Marina
    Scheithauer, Bernd W.
    Halliday, William
    Hawkins, Cynthia
    Rosenblum, Marc K.
    Burger, Peter C.
    Eberhart, Charles G.
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2009, 33 (02) : 211 - 217
  • [24] Gleize V, 2015, ANN NEUROL
  • [25] IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma
    Gorovets, Daniel
    Kannan, Kasthuri
    Shen, Ronglai
    Kastenhuber, Edward R.
    Islamdoust, Nasrin
    Campos, Carl
    Pentsova, Elena
    Heguy, Adriana
    Jhanwar, Suresh C.
    Mellinghoff, Ingo K.
    Chan, Timothy A.
    Huse, Jason T.
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (09) : 2490 - 2501
  • [26] Immunohistochemical analysis of INI1 protein in malignant pediatric CNS tumors: Lack of INI1 in atypical teratoid/rhabdoid tumors and in a fraction of primitive neuroectodermal tumors without rhabdoid phenotype
    Haberler, Christine
    Laggner, Ute
    Slavc, Irene
    Czech, Thomas
    Ambros, Inge M.
    Ambros, Peter F.
    Budka, Herbert
    Hainfellner, Johannes A.
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2006, 30 (11) : 1462 - 1468
  • [27] Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
    Hartmann, Christian
    Hentschel, Bettina
    Wick, Wolfgang
    Capper, David
    Felsberg, Joerg
    Simon, Matthias
    Westphal, Manfred
    Schackert, Gabriele
    Meyermann, Richard
    Pietsch, Torsten
    Reifenberger, Guido
    Weller, Michael
    Loeffler, Markus
    von Deimling, Andreas
    [J]. ACTA NEUROPATHOLOGICA, 2010, 120 (06) : 707 - 718
  • [28] MGMT gene silencing and benefit from temozolomide in glioblastoma
    Hegi, ME
    Diserens, A
    Gorlia, T
    Hamou, M
    de Tribolet, N
    Weller, M
    Kros, JM
    Hainfellner, JA
    Mason, W
    Mariani, L
    Bromberg, JEC
    Hau, P
    Mirimanoff, RO
    Cairncross, JG
    Janzer, RC
    Stupp, R
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) : 997 - 1003
  • [29] Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial
    Hegi, Monika E.
    Janzer, Robert-Charles
    Lambiv, Wanyu L.
    Gorlia, Thierry
    Kouwenhoven, Mathilde C. M.
    Hartmann, Christian
    von Deimling, Andreas
    Martinet, Danielle
    Schmutz, Nathalie Besuchet
    Diserens, Annie-Claire
    Hamou, Marie-France
    Bady, Pierre
    Weller, Michael
    van den Bent, Martin J.
    Mason, Warren P.
    Mirimanoff, Rene-Olivier
    Stupp, Roger
    Mokhtari, Karima
    Wesseling, Pieter
    [J]. ACTA NEUROPATHOLOGICA, 2012, 123 (06) : 841 - 852
  • [30] Herrlinger U, 2016, ACTA NEUROPATHOL, V131, P309, DOI 10.1007/s00401-015-1495-z